Brokerages expect that Catabasis Pharmaceuticals Inc (NASDAQ:CATB) will report earnings per share (EPS) of ($0.27) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Catabasis Pharmaceuticals’ earnings, with estimates ranging from ($0.30) to ($0.23). Catabasis Pharmaceuticals posted earnings per share of ($0.32) during the same quarter last year, which would indicate a positive year over year growth rate of 15.6%. The company is expected to report its next quarterly earnings results on Thursday, August 9th.
On average, analysts expect that Catabasis Pharmaceuticals will report full year earnings of ($1.04) per share for the current fiscal year, with EPS estimates ranging from ($1.22) to ($0.86). For the next fiscal year, analysts forecast that the firm will report earnings of ($1.56) per share, with EPS estimates ranging from ($1.90) to ($1.22). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Catabasis Pharmaceuticals.
Catabasis Pharmaceuticals (NASDAQ:CATB) last announced its quarterly earnings results on Thursday, May 10th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.06).
Several equities research analysts have recently issued reports on the company. Zacks Investment Research upgraded Catabasis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 price target for the company in a report on Tuesday, March 20th. Wedbush lifted their price target on Catabasis Pharmaceuticals from $5.00 to $6.00 and gave the company an “outperform” rating in a report on Tuesday, March 20th. Finally, ValuEngine upgraded Catabasis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 2nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $5.18.
A number of institutional investors and hedge funds have recently bought and sold shares of CATB. Renaissance Technologies LLC lifted its holdings in Catabasis Pharmaceuticals by 167.2% in the 4th quarter. Renaissance Technologies LLC now owns 468,700 shares of the biotechnology company’s stock worth $698,000 after purchasing an additional 293,300 shares during the last quarter. Deutsche Bank AG acquired a new stake in Catabasis Pharmaceuticals in the 4th quarter worth approximately $335,000. Finally, Geode Capital Management LLC lifted its holdings in Catabasis Pharmaceuticals by 146.1% in the 4th quarter. Geode Capital Management LLC now owns 76,612 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 45,476 shares during the last quarter. Hedge funds and other institutional investors own 25.32% of the company’s stock.
Shares of Catabasis Pharmaceuticals traded down $0.02, hitting $1.58, during trading on Monday, Marketbeat Ratings reports. 1,100 shares of the stock traded hands, compared to its average volume of 724,953. The firm has a market cap of $46.46 million, a price-to-earnings ratio of -1.27 and a beta of 0.70. Catabasis Pharmaceuticals has a twelve month low of $1.61 and a twelve month high of $1.61.
Catabasis Pharmaceuticals Company Profile
Catabasis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule, which completed Phase II clinical trial for the treatment of duchenne muscular dystrophy (DMD), as well as Phase I clinical trial for the treatment of additional rare diseases.
Get a free copy of the Zacks research report on Catabasis Pharmaceuticals (CATB)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.